Ramon Gil, MD
Neurology · Port Charlotte, FLNPI 1700847597
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $503,399 of the $662,729 with a category attached, or 76.0%. 37 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 27.7% of the total. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,223 payments — averaging $541.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$183K
- Amneal Pharmaceuticals LLC$116K
- MDD US Operations, LLC$97K
- Kyowa Kirin, Inc.$74K
- Acadia Pharmaceuticals Inc$52K
- Adamas Pharmaceuticals, Inc.$32K
- plus $108K from 31 others
Across 686 payments — averaging $1863.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sage Therapeutics, LLC$337K
- H. Lundbeck A S$229K
- Sunovion Pharmaceuticals Inc.$185K
- Amneal Pharmaceuticals LLC$166K
- AbbVie$141K
- Acadia Pharmaceuticals Inc$120K
- plus $100K from 4 others
What the payments were for
- Consulting fees$75,52211%
- Speaking & faculty fees$503,39976%
- Travel & lodging$47,3497%
- Food & beverage$29,6864%
- Education$6,7731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$662,729 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 651 | $1,206,379 |
| NuplazidPimavanserin Tartrate | 100 | $615,397 |
| GocovriAmantadine Hcl | 156 | $525,150 |
| NortheraDroxidopa | 11 | $393,974 |
| Droxidopa | 84 | $384,748 |
| IngrezzaValbenazine Tosylate | 29 | $240,822 |
| NourianzIstradefylline | 27 | $83,747 |
| OngentysOpicapone | 66 | $73,353 |
| RexultiBrexpiprazole | 34 | $71,073 |
| InbrijaLevodopa | 21 | $43,732 |
| Rasagiline Mesylate | 112 | $27,492 |
| TrintellixVortioxetine Hydrobromide | 31 | $27,339 |
| Rivastigmine | 59 | $18,038 |
| DysportAbobotulinumtoxina | 18 | $16,237 |
| XadagoSafinamide Mesylate | 14 | $15,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $116,186 | $1,206,379651 claims |
| Acadia Pharmaceuticals IncNuplazid | $51,820 | $615,397100 claims |
| MDD US Operations, LLCGocovri | $97,393 | $525,150156 claims |
| Lundbeck LLCNorthera | $24,365 | $393,97411 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $183,321 | $314,17695 claims |
| Kyowa Kirin, Inc.Nourianz | $73,739 | $83,74727 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $126 | $71,07334 claims |
| Acorda Therapeutics, IncInbrija | $3,017 | $43,73221 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $168 | $27,33931 claims |
| Ipsen Biopharmaceuticals, IncDysport | $2,529 | $16,23718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.
Other neurology in Port Charlotte
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.